Rigel Pharmaceuticals | RIGL - Passivo Circulante





Passivo Circulante Alterar Data
Agenus USD 249.24M 74.25M 2026-03
Amgen USD 24.96B 534M 2026-03
Anika Therapeutics USD 20.97M 942K 2026-03
Arrowhead Research USD 295.22M 52.2M 2026-03
AstraZeneca USD 32.57B 1.95B 2026-03
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
Bristol-Myers Squibb USD 19.16B 4.26B 2026-03
Celldex Therapeutics USD 51.47M 481K 2026-03
Daiichi Sankyo JPY 778.55B 77.51B 2025-12
Eli Lilly USD 36.63B 1.41B 2026-03
Halozyme Therapeutics USD 363.21M 186.12M 2026-03
Heron Therapeutics USD 90.52M 5.58M 2026-03
Intrexon USD 23.02M 38K 2024-06
Ionis Pharmaceuticals USD 717M 66M 2026-03
Karyopharm Therapeutics USD 92.06M 4.9M 2025-12
Ligand Pharmaceuticals USD 40.67M 3.22M 2026-03
MacroGenics USD 95.94M 52.82M 2026-03
Neurocrine Biosciences USD 831.7M 88.3M 2026-03
Pfizer USD 34.35B 2.64B 2026-03
Regeneron Pharmaceuticals USD 5.11B 739.3M 2026-03
Rigel Pharmaceuticals USD 94.4M 7.76M 2025-09
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Ultragenyx Pharmaceutical USD 325M 59M 2026-03
Veracyte USD 56.11M 3.82M 2026-03